{
  "disease": "hypertension",
  "original_target": null,
  "failed_trials_count": 3,
  "failure_patterns": {
    "safety_issues": 0,
    "efficacy_issues": 0,
    "recruitment_issues": 1,
    "business_reasons": 0,
    "other_reasons": 2,
    "unknown": 0
  },
  "side_effects_analysis": {
    "safety_terminations_count": 0,
    "safety_terminations": [],
    "why_stopped_categories": {
      "safety_related": 0,
      "efficacy_related": 0,
      "business_related": 1,
      "other": 2
    },
    "why_stopped_details": {
      "safety_related": [],
      "efficacy_related": [],
      "business_related": [
        "The study was discontinued early due to lack of funding and slow enrollment"
      ],
      "other": [
        "Refusal of CPP to extend the period of inclusion",
        "IRB Approval Lapse - working on resubmission"
      ]
    },
    "adverse_events_summary": {},
    "side_effects_patterns": {
      "patterns": [],
      "drug_classes_affected": [],
      "organ_systems": []
    },
    "repurposing_opportunities": []
  },
  "failure_analysis": {
    "failed_drugs_analysis": [
      {
        "drug_name": "Omega-3",
        "mechanism": "Omega-3 fatty acids are believed to exert anti-inflammatory effects and improve endothelial function, potentially leading to vasodilation and reduced blood pressure.",
        "failure_type": "business_related",
        "biological_insight": "The mechanism of action may not have been sufficiently effective in the hypertensive population studied, and the trial was terminated due to funding issues rather than safety or efficacy concerns."
      }
    ],
    "disease_insights": "The failures highlight the complexity of hypertension as a multifactorial disease, where single interventions may not adequately address the underlying pathophysiology, such as vascular remodeling and systemic inflammation.",
    "failed_pathways": [
      "Endothelial dysfunction",
      "Inflammatory pathways"
    ],
    "alternative_mechanisms": [
      "Renin-angiotensin-aldosterone system (RAAS) inhibitors",
      "Calcium channel blockers"
    ],
    "key_biological_challenges": [
      "Heterogeneity of hypertensive patients",
      "Need for combination therapies to address multiple pathways"
    ]
  },
  "repurposing_candidates": [
    {
      "drug": "BIA 5-453",
      "total_trials": 2,
      "completed": 2,
      "failed": 0,
      "ongoing": 0,
      "phases": [
        "PHASE1"
      ],
      "trials": [
        "NCT02840565",
        "NCT03099226"
      ],
      "repurposing_score": 65.0,
      "chembl_id": "CHEMBL3233142",
      "max_phase": 1,
      "resolution_source": "chembl_synonym_contains_via_llm"
    },
    {
      "drug": "CKD-348 F1",
      "total_trials": 1,
      "completed": 1,
      "failed": 0,
      "ongoing": 0,
      "phases": [
        "PHASE1"
      ],
      "trials": [
        "NCT04258865"
      ],
      "repurposing_score": 55.0,
      "chembl_id": null,
      "max_phase": null,
      "resolution_source": "not_found"
    },
    {
      "drug": "CKD-348 F2",
      "total_trials": 1,
      "completed": 1,
      "failed": 0,
      "ongoing": 0,
      "phases": [
        "PHASE1"
      ],
      "trials": [
        "NCT04258865"
      ],
      "repurposing_score": 55.0,
      "chembl_id": null,
      "max_phase": null,
      "resolution_source": "not_found"
    },
    {
      "drug": "CKD-828, D097, D337",
      "total_trials": 1,
      "completed": 1,
      "failed": 0,
      "ongoing": 0,
      "phases": [
        "PHASE1"
      ],
      "trials": [
        "NCT04258865"
      ],
      "repurposing_score": 55.0,
      "chembl_id": null,
      "max_phase": null,
      "resolution_source": "not_found"
    },
    {
      "drug": "Polypill",
      "total_trials": 1,
      "completed": 0,
      "failed": 0,
      "ongoing": 1,
      "phases": [
        "PHASE2",
        "PHASE1"
      ],
      "trials": [
        "NCT06143566"
      ],
      "repurposing_score": 55.0,
      "chembl_id": null,
      "max_phase": null,
      "resolution_source": "not_found"
    },
    {
      "drug": "Combined prescription of the individual medications",
      "total_trials": 1,
      "completed": 0,
      "failed": 0,
      "ongoing": 1,
      "phases": [
        "PHASE2",
        "PHASE1"
      ],
      "trials": [
        "NCT06143566"
      ],
      "repurposing_score": 55.0,
      "chembl_id": null,
      "max_phase": null,
      "resolution_source": "not_found"
    },
    {
      "drug": "PRO-122",
      "total_trials": 1,
      "completed": 1,
      "failed": 0,
      "ongoing": 0,
      "phases": [
        "PHASE1"
      ],
      "trials": [
        "NCT03966365"
      ],
      "repurposing_score": 55.0,
      "chembl_id": null,
      "max_phase": null,
      "resolution_source": "not_found"
    },
    {
      "drug": "Krytantek Ofteno\u00ae",
      "total_trials": 1,
      "completed": 1,
      "failed": 0,
      "ongoing": 0,
      "phases": [
        "PHASE1"
      ],
      "trials": [
        "NCT03966365"
      ],
      "repurposing_score": 55.0,
      "chembl_id": "CHEMBL1372341",
      "max_phase": 1,
      "resolution_source": "chembl_synonym_exact_via_llm"
    },
    {
      "drug": "Cholecalciferol",
      "total_trials": 1,
      "completed": 1,
      "failed": 0,
      "ongoing": 0,
      "phases": [
        "PHASE2"
      ],
      "trials": [
        "NCT01166165"
      ],
      "repurposing_score": 50.0,
      "chembl_id": "CHEMBL1042",
      "max_phase": 2,
      "resolution_source": "chembl_synonym_exact_via_llm"
    },
    {
      "drug": "Sildenafil",
      "total_trials": 2,
      "completed": 1,
      "failed": 1,
      "ongoing": 0,
      "phases": [
        "PHASE4",
        "PHASE2"
      ],
      "trials": [
        "NCT01889966",
        "NCT00492531"
      ],
      "repurposing_score": 50.0,
      "chembl_id": "CHEMBL192",
      "max_phase": 2,
      "resolution_source": "chembl_synonym_exact"
    }
  ],
  "candidate_safety_profiles": [
    {
      "drug_name": "BIA 5-453",
      "chembl_id": "CHEMBL3233142",
      "fda_adverse_events": {
        "total_reports": 0,
        "top_adverse_events": [],
        "data_source": "Not available"
      },
      "drug_interactions": null,
      "contraindications": [],
      "mechanism_summary": {},
      "safety_score": 65.0
    },
    {
      "drug_name": "CKD-348 F1",
      "chembl_id": null,
      "fda_adverse_events": {
        "total_reports": 0,
        "top_adverse_events": [],
        "data_source": "Not available"
      },
      "drug_interactions": null,
      "contraindications": [],
      "mechanism_summary": {},
      "safety_score": 55.0
    },
    {
      "drug_name": "CKD-348 F2",
      "chembl_id": null,
      "fda_adverse_events": {
        "total_reports": 0,
        "top_adverse_events": [],
        "data_source": "Not available"
      },
      "drug_interactions": null,
      "contraindications": [],
      "mechanism_summary": {},
      "safety_score": 55.0
    },
    {
      "drug_name": "CKD-828, D097, D337",
      "chembl_id": null,
      "fda_adverse_events": {
        "total_reports": 0,
        "top_adverse_events": [],
        "data_source": "Not available"
      },
      "drug_interactions": null,
      "contraindications": [],
      "mechanism_summary": {},
      "safety_score": 55.0
    },
    {
      "drug_name": "Polypill",
      "chembl_id": null,
      "fda_adverse_events": {
        "total_reports": 0,
        "top_adverse_events": [],
        "data_source": "Not available"
      },
      "drug_interactions": null,
      "contraindications": [],
      "mechanism_summary": {},
      "safety_score": 55.0
    }
  ],
  "alternative_targets": [
    {
      "target": "SGLT2",
      "inhibitor_count": 50,
      "most_potent_ic50": 1.15,
      "most_advanced_compound": {
        "chembl_id": "CHEMBL1770248",
        "phase": "4.0"
      },
      "clinical_trials": {
        "total": 20,
        "recruiting": 4,
        "completed": 12,
        "failed": 1,
        "phases": {
          "PHASE1": 5,
          "PHASE2": 5,
          "PHASE3": 2
        }
      },
      "literature_count": 10,
      "development_score": 0.8,
      "pdb_structures": [
        {
          "pdb_id": "7VSI",
          "title": "Structure of human SGLT2-MAP17 complex bound with empagliflozin",
          "resolution": 2.95,
          "method": "ELECTRON MICROSCOPY"
        },
        {
          "pdb_id": "8HDH",
          "title": "Structure of human SGLT2-MAP17 complex with Canagliflozin",
          "resolution": 3.1,
          "method": "ELECTRON MICROSCOPY"
        },
        {
          "pdb_id": "8HG7",
          "title": "Structure of human SGLT2-MAP17 complex with Sotagliflozin",
          "resolution": 3.1,
          "method": "ELECTRON MICROSCOPY"
        },
        {
          "pdb_id": "8HEZ",
          "title": "Structure of human SGLT2-MAP17 complex with Dapagliflozin",
          "resolution": 2.8,
          "method": "ELECTRON MICROSCOPY"
        },
        {
          "pdb_id": "8HB0",
          "title": "Structure of human SGLT2-MAP17 complex with TA1887",
          "resolution": 2.9,
          "method": "ELECTRON MICROSCOPY"
        }
      ],
      "rationale": "SGLT2 inhibitors have shown promise in reducing blood pressure through diuresis and improved cardiovascular outcomes, addressing fluid overload which is a contributing factor in hypertension.",
      "confidence": 0.85
    },
    {
      "target": "Endothelin Receptor Antagonists",
      "inhibitor_count": 0,
      "most_potent_ic50": null,
      "most_advanced_compound": {
        "chembl_id": null,
        "phase": null
      },
      "clinical_trials": {
        "total": 20,
        "recruiting": 3,
        "completed": 8,
        "failed": 6,
        "phases": {
          "PHASE1": 2,
          "PHASE2": 2,
          "PHASE3": 8
        }
      },
      "literature_count": 10,
      "development_score": 0.47,
      "pdb_structures": [
        {
          "pdb_id": "8JVJ",
          "title": "Structure of human TRPV4 with antagonist A2 and RhoA",
          "resolution": 3.44,
          "method": "ELECTRON MICROSCOPY"
        }
      ],
      "rationale": "Targeting endothelin-1, a potent vasoconstrictor, could help mitigate vascular remodeling and systemic inflammation, which are key factors in hypertension.",
      "confidence": 0.75
    },
    {
      "target": "Neprilysin Inhibitors",
      "inhibitor_count": 0,
      "most_potent_ic50": null,
      "most_advanced_compound": {
        "chembl_id": null,
        "phase": null
      },
      "clinical_trials": {
        "total": 20,
        "recruiting": 7,
        "completed": 9,
        "failed": 0,
        "phases": {
          "PHASE1": 0,
          "PHASE2": 1,
          "PHASE3": 4
        }
      },
      "literature_count": 10,
      "development_score": 0.5,
      "pdb_structures": [
        {
          "pdb_id": "1R1H",
          "title": "STRUCTURAL ANALYSIS OF NEPRILYSIN WITH VARIOUS SPECIFIC AND POTENT INHIBITORS",
          "resolution": 1.95,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "1R1J",
          "title": "STRUCTURAL ANALYSIS OF NEPRILYSIN WITH VARIOUS SPECIFIC AND POTENT INHIBITORS",
          "resolution": 2.35,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "1Y8J",
          "title": "Crystal Structure of human NEP complexed with an imidazo[4,5-c]pyridine inhibitor",
          "resolution": 2.25,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "1R1I",
          "title": "STRUCTURAL ANALYSIS OF NEPRILYSIN WITH VARIOUS SPECIFIC AND POTENT INHIBITORS",
          "resolution": 2.6,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "6THP",
          "title": "Neprilysin in complex with the inhibitor (R)-4-(1-carboxy-3-(3'-chlorobiphenyl-4-yl)propan-2-ylamino)-4-oxobutanoic acid",
          "resolution": 2.54,
          "method": "X-RAY DIFFRACTION"
        }
      ],
      "rationale": "Neprilysin inhibitors can enhance levels of natriuretic peptides, which promote vasodilation and natriuresis, addressing the imbalance in vasodilatory and vasoconstrictive factors in hypertension.",
      "confidence": 0.8
    },
    {
      "target": "CGRP Receptor Antagonists",
      "inhibitor_count": 0,
      "most_potent_ic50": null,
      "most_advanced_compound": {
        "chembl_id": null,
        "phase": null
      },
      "clinical_trials": {
        "total": 20,
        "recruiting": 4,
        "completed": 11,
        "failed": 2,
        "phases": {
          "PHASE1": 5,
          "PHASE2": 3,
          "PHASE3": 0
        }
      },
      "literature_count": 10,
      "development_score": 0.39,
      "pdb_structures": [
        {
          "pdb_id": "8AX7",
          "title": "Crystal structure of a CGRP receptor ectodomain heterodimer bound to macrocyclic inhibitor HTL0031448",
          "resolution": 1.65,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "8AX6",
          "title": "Crystal structure of a CGRP receptor ectodomain heterodimer bound to macrocyclic inhibitor HTL0029882",
          "resolution": 1.9,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "7P0F",
          "title": "Crystal structure of a CGRP receptor ectodomain heterodimer bound to macrocyclic inhibitor HTL0028125",
          "resolution": 1.85,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "7P0I",
          "title": "Crystal structure of a CGRP receptor ectodomain heterodimer bound to macrocyclic inhibitor Compound 13",
          "resolution": 2.3,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "8AX5",
          "title": "Crystal structure of a CGRP receptor ectodomain heterodimer bound to macrocyclic inhibitor HTL0029881",
          "resolution": 2.75,
          "method": "X-RAY DIFFRACTION"
        }
      ],
      "rationale": "Calcitonin gene-related peptide (CGRP) plays a role in vasodilation; antagonizing its receptor may help in managing hypertension by promoting vascular relaxation.",
      "confidence": 0.7
    },
    {
      "target": "KCNQ Potassium Channels",
      "inhibitor_count": 0,
      "most_potent_ic50": null,
      "most_advanced_compound": {
        "chembl_id": null,
        "phase": null
      },
      "clinical_trials": {
        "total": 1,
        "recruiting": 0,
        "completed": 1,
        "failed": 0,
        "phases": {
          "PHASE1": 0,
          "PHASE2": 1,
          "PHASE3": 0
        }
      },
      "literature_count": 10,
      "development_score": 0.3,
      "pdb_structures": [
        {
          "pdb_id": "7CR0",
          "title": "human KCNQ2 in apo state",
          "resolution": 3.1,
          "method": "ELECTRON MICROSCOPY"
        },
        {
          "pdb_id": "7CR1",
          "title": "human KCNQ2 in complex with ztz240",
          "resolution": 3.4,
          "method": "ELECTRON MICROSCOPY"
        },
        {
          "pdb_id": "7CR2",
          "title": "human KCNQ2 in complex with retigabine",
          "resolution": 3.2,
          "method": "ELECTRON MICROSCOPY"
        },
        {
          "pdb_id": "2OVC",
          "title": "Crystal structure of a coiled-coil tetramerization domain from Kv7.4 channels",
          "resolution": 2.07,
          "method": "X-RAY DIFFRACTION"
        },
        {
          "pdb_id": "5X0S",
          "title": "Solution NMR structure of peptide toxin SsTx from Scolopendra subspinipes mutilans",
          "resolution": null,
          "method": "SOLUTION NMR"
        }
      ],
      "rationale": "Activating KCNQ potassium channels can lead to hyperpolarization of vascular smooth muscle cells, promoting vasodilation and addressing hypertension.",
      "confidence": 0.65
    }
  ],
  "failed_trials_sample": [
    {
      "nct_id": "NCT00935766",
      "title": "Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries",
      "status": "TERMINATED",
      "phase": [
        "PHASE3"
      ],
      "conditions": [
        "Metabolic Diseases",
        "Endocrine System Diseases",
        "Heart Disease",
        "Vascular Diseases",
        "Diabetes",
        "Cardiovascular Disease",
        "Glucose Metabolism Disorders",
        "Hypertension"
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Omega-3",
          "description": "Subjects meeting eligibility criteria will be randomized to receive a supply of omega-3-acid ethyl esters or placebo, and instructed to take 4 capsules daily. A 3-month supply of study drug will be given following randomization and at 3, 6, and 9 months. Subjects will be asked to bring unused supplies to each quarterly visit for ascertainment of adherence."
        },
        {
          "type": "DRUG",
          "name": "Placebo",
          "description": ""
        }
      ],
      "start_date": "2009-09",
      "completion_date": "2012-03",
      "enrollment": 76,
      "primary_outcomes": [
        {
          "measure": "Change in Pulse Wave Velocity in Active vs. Placebo-treated Patients.",
          "description": "We conducted a prospective, randomized; double-blinded study of omega-3 fatty acids among 60 Latino and White hypertensive patients at risk for CVD. Patients received either 4-g omega-3 fatty acids or matched placebo daily. The principal outcome measure was change in brachial-ankle PWV.\n\n.",
          "time_frame": "Baseline, 3 months"
        }
      ],
      "why_stopped": "The study was discontinued early due to lack of funding and slow enrollment",
      "results_available": true
    },
    {
      "nct_id": "NCT02525926",
      "title": "Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension",
      "status": "TERMINATED",
      "phase": [
        "NA"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "type": "PROCEDURE",
          "name": "denervation",
          "description": "The examination proceeds under rigorous aseptic technique. Femoral, jugular or brachial venous access will be performed. A flexible catheter is first introduced across a 7-Fr venous introducer, and passed through the right heart chambers toward the origin of the pulmonary arteries. The pressures in the right heart chambers and the pulmonary artery will be measured. At the end of the examination, the catheter is removed, a dressing is applied and the venous puncture is compressed by hand."
        },
        {
          "type": "PROCEDURE",
          "name": "sham procedure",
          "description": "Right heart catheterism is mandatory in PAH patients care (for diagnosis and during follow-up) and will serve as a \" sham \" procedure. A usually performed and after a venous punction, cardiac outpout and pulmonary artery pressures will be recorded.\n\nAcoustically isolated headphones will be given to patients during the procedure in order to assure simple-blind during the study."
        }
      ],
      "start_date": "2016-02-04",
      "completion_date": "2024-10-17",
      "enrollment": 1,
      "primary_outcomes": [
        {
          "measure": "Mean pulmonary artery pressure (in mmHg) measured during right heart catheterization",
          "description": "",
          "time_frame": "at 6 month"
        }
      ],
      "why_stopped": "Refusal of CPP to extend the period of inclusion",
      "results_available": false
    },
    {
      "nct_id": "NCT05874726",
      "title": "Biological Sample Repository for Gastrointestinal Disorders",
      "status": "SUSPENDED",
      "phase": [],
      "conditions": [
        "Obesity",
        "Obesity, Morbid",
        "Obesity, Primary",
        "Gastro-Intestinal Disorder",
        "Overweight and Obesity",
        "Overweight",
        "Overweight or Obesity",
        "Diabetes Type 2",
        "Diabetes Mellitus",
        "Diabetes Mellitus, Type 2",
        "Hypertension",
        "Hyperlipidemias",
        "Sleep Apnea",
        "GERD",
        "Gastroesophageal Reflux",
        "Musculoskeletal Pain Disorder",
        "Cancer"
      ],
      "interventions": [
        {
          "type": "DIAGNOSTIC_TEST",
          "name": "Blood Collection",
          "description": "Blood collection via venipuncture"
        },
        {
          "type": "DIAGNOSTIC_TEST",
          "name": "Urine Collection",
          "description": "Free catch urine sample collection"
        },
        {
          "type": "DIAGNOSTIC_TEST",
          "name": "Tissue Sample Collection",
          "description": "Tissue (gastric, duodenum, jejunum and ileum - number of biopsies will be 3-4 from each site, ranging in size from 4-7mm) - These samples collected will be extra biopsies that are taken for research purposes during a clinically planned endoscopy for which biopsies are being planned."
        }
      ],
      "start_date": "2023-07-19",
      "completion_date": "2029-04",
      "enrollment": 500,
      "primary_outcomes": [
        {
          "measure": "Serum sample repository",
          "description": "Blood (10 ml) will be collected from the enrolled subjects, serum will be extracted and stored at -80 degrees for up to 10 years.",
          "time_frame": "Change from Baseline to 10 years."
        },
        {
          "measure": "Urine sample repository",
          "description": "Urine (5 ml) will be collected via free catch method and stored at -80 degrees C for up to 10 years.",
          "time_frame": "Change from Baseline to 10 years."
        },
        {
          "measure": "Tissue sample repository",
          "description": "Tissue samples (gastric, duodenum, jejunum and ileum - number of biopsies will be 3-4 from each site, ranging in size from 4-7mm) will be collected during a scheduled endoscopic examination. Biopsy tissue will be collected with a large capacity biopsy forceps and deposited into a conical vial containing a freshly prepared balanced salt solution including a HEPES buffer at the bedside, using 5mL of buffered salt solution per 5-10 mm3 of tissue biopsy, at 4 degrees C. Tissue will be stored at -80\u2070C until they are \"used up\" or for up to 10 years from collection.",
          "time_frame": "Change from Baseline to 10 years."
        }
      ],
      "why_stopped": "IRB Approval Lapse - working on resubmission",
      "results_available": false
    }
  ],
  "metadata": {
    "timestamp": "2025-07-29T13:44:13.239691",
    "query": {
      "disease": "hypertension",
      "target": null
    },
    "version": "1.0"
  }
}